These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26251419)

  • 1. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.
    Dalm SU; Sieuwerts AM; Look MP; Melis M; van Deurzen CH; Foekens JA; de Jong M; Martens JW
    J Nucl Med; 2015 Oct; 56(10):1487-93. PubMed ID: 26251419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer.
    Dalm SU; Schrijver WA; Sieuwerts AM; Look MP; Ziel-van der Made AC; de Weerd V; Martens JW; van Diest PJ; de Jong M; van Deurzen CH
    PLoS One; 2017; 12(1):e0170536. PubMed ID: 28107508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
    Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
    J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.
    Morgat C; MacGrogan G; Brouste V; Vélasco V; Sévenet N; Bonnefoi H; Fernandez P; Debled M; Hindié E
    J Nucl Med; 2017 Sep; 58(9):1401-1407. PubMed ID: 28280221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
    Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review.
    Baun C; Naghavi-Behzad M; Hildebrandt MG; Gerke O; Thisgaard H
    Semin Nucl Med; 2024 Mar; 54(2):256-269. PubMed ID: 38342656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
    Goetz MP; Suman VJ; Ingle JN; Nibbe AM; Visscher DW; Reynolds CA; Lingle WL; Erlander M; Ma XJ; Sgroi DC; Perez EA; Couch FJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2080-7. PubMed ID: 16609019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
    Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
    Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
    Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
    Helleman J; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Klijn JG; Sleijfer S; Foekens JA; Berns EM
    Clin Cancer Res; 2008 Sep; 14(17):5555-64. PubMed ID: 18765548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
    Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
    J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using second harmonic generation to predict patient outcome in solid tumors.
    Burke K; Smid M; Dawes RP; Timmermans MA; Salzman P; van Deurzen CH; Beer DG; Foekens JA; Brown E
    BMC Cancer; 2015 Nov; 15():929. PubMed ID: 26603532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
    Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
    Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.